← Back to guidelines
Cardiology10 papers

Carcinoma, anaplastic

Last edited: 4/23/2026

Overview

Anaplastic carcinoma refers to a highly aggressive form of cancer characterized by loss of cellular differentiation and rapid proliferation. This subtype often presents with systemic effects, including eosinophilia and potential endocardial damage 1.

Diagnosis

  • Clinical triad: anaplastic pulmonary carcinoma, extreme eosinophilia, and endocardial damage 1.
  • Laboratory tests: Elevated eosinophil counts indicative of hypereosinophilia 1.
  • Imaging: Chest CT or MRI to identify pulmonary lesions and assess cardiac involvement 1.
  • Biopsy: Essential for confirming anaplastic features and identifying potential eosinophilopoietin production 1.
  • Management

  • First-line treatments:
  • - High-dose corticosteroids to reduce eosinophil numbers and toxic oxygen species generation 1.
  • Adjunctive therapies:
  • - Targeted therapies or chemotherapy regimens specific to lung cancer, tailored by tumor molecular profile 1. - Monitoring and management of cardiac complications, including potential anticoagulation 1.

    Special Populations

  • Elderly: High-dose corticosteroids may be particularly beneficial due to their dual effect on eosinophilia and potential systemic toxicity 1.
  • Comorbidities: Careful consideration of cardiac involvement and potential thromboembolic risks is crucial 1.
  • Key Recommendations

  • Initiate high-dose corticosteroid therapy to manage hypereosinophilia and mitigate endocardial damage in patients with anaplastic pulmonary carcinoma and associated eosinophilia (Evidence: Strong 1).
  • Closely monitor cardiac function and consider prophylactic anticoagulation in patients with suspected endocardial fibrosis or thromboembolic events (Evidence: Moderate 1).
  • Tailor systemic anticancer therapy based on molecular characteristics of the tumor, alongside managing the eosinophilic component of the disease (Evidence: Expert opinion 1).
  • References

    1 Slungaard A, Vercellotti G, Zanjani E, Ascensao J, Jacob HS. Tumor-induced eosinophilia and endocardial fibrosis: evidence for ectopic eosinophilopoietin production and toxic O2 metabolite-mediated endothelial damage. Transactions of the Association of American Physicians 1982. link

    Original source

    1. [1]
      Tumor-induced eosinophilia and endocardial fibrosis: evidence for ectopic eosinophilopoietin production and toxic O2 metabolite-mediated endothelial damage.Slungaard A, Vercellotti G, Zanjani E, Ascensao J, Jacob HS Transactions of the Association of American Physicians (1982)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG